{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T02:18:14Z","timestamp":1774318694921,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.leukres.2018.09.017","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T01:52:52Z","timestamp":1538445172000},"page":"68-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["An mTORC1\/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function"],"prefix":"10.1016","volume":"74","author":[{"given":"Yimamu","family":"Maimaitili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Inase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiharu","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Kitao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Mizutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Kakiuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Shimono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sonoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironobu","family":"Minami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2018.09.017_bib0005","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"issue":"1-2","key":"10.1016\/j.leukres.2018.09.017_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.imlet.2013.09.013","article-title":"Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors","volume":"155","author":"Tettamanti","year":"2013","journal-title":"Immunol. Lett."},{"issue":"4","key":"10.1016\/j.leukres.2018.09.017_bib0015","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","article-title":"Expression of normal myeloid-associated antigens by acute leukemia cells","volume":"67","author":"Dinndorf","year":"1986","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.09.017_bib0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.leukres.2006.03.022","article-title":"Immunophenotyping of surface antigens in acute myeloid leukemia by flow cytometry after red blood cell lysis","volume":"31","author":"Schwonzen","year":"2007","journal-title":"Leuk. Res."},{"issue":"26","key":"10.1016\/j.leukres.2018.09.017_bib0025","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1182\/blood-2011-11-325050","article-title":"Acute myeloid leukemia stem cells and CD33-targeted immunotherapy","volume":"119","author":"Walter","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2018.09.017_bib0030","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3324\/haematol.2014.112748","article-title":"Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia","volume":"100","author":"O\u2019Hear","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.leukres.2018.09.017_bib0035","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/leu.2017.187","article-title":"Gemtuzumab ozogamicin in acute myeloid leukemia","volume":"31","author":"Godwin","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2018.09.017_bib0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","article-title":"Fate of antibody-drug conjugates in Cancer cells","volume":"37","author":"Chalouni","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2018.09.017_bib0045","first-page":"2123","article-title":"Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells","volume":"56","author":"Press","year":"1996","journal-title":"Cancer Res."},{"key":"10.1016\/j.leukres.2018.09.017_bib0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/CIA.S3968","article-title":"Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin","volume":"4","author":"Duong","year":"2009","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.leukres.2018.09.017_bib0055","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.exphem.2017.06.007","article-title":"Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia","volume":"54","author":"Laing","year":"2017","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2018.09.017_bib0060","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1073\/pnas.95.1.102","article-title":"Supercoiling affects the accessibility of glutathione to DNA-bound molecules: positive supercoiling inhibits calicheamicin-induced DNA damage","volume":"95","author":"LaMarr","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"24","key":"10.1016\/j.leukres.2018.09.017_bib0065","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.09.017_bib0070","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/leu.2012.178","article-title":"Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin","volume":"27","author":"Kurimoto","year":"2013","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.leukres.2018.09.017_bib0075","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1182\/blood-2002-07-2311","article-title":"Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3","volume":"101","author":"Amico","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2018.09.017_bib0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/cr.2013.11","article-title":"Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion","volume":"23","author":"Zhou","year":"2013","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.leukres.2018.09.017_bib0085","doi-asserted-by":"crossref","first-page":"427","DOI":"10.18632\/oncotarget.2813","article-title":"DNA damage-induced S and G2\/M cell cycle arrest requires mTORC2-dependent regulation of Chk1","volume":"6","author":"Selvarajah","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.leukres.2018.09.017_bib0090","first-page":"981","article-title":"Establishment of a human myeloid cell line with trisomy 8 derived from overt leukemia following myelodysplastic syndrome","volume":"90","author":"Matsuoka","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2018.09.017_bib0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2016.12.010","article-title":"Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model","volume":"389","author":"Wu","year":"2017","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.leukres.2018.09.017_bib0100","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.leukres.2018.09.017_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijporl.2016.04.008","article-title":"The effects of the antioxidant alpha-tocopherol succinate on cisplatin-induced ototoxicity in HEI-OC1 auditory cells","volume":"86","author":"Kim","year":"2016","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"issue":"26","key":"10.1016\/j.leukres.2018.09.017_bib0110","doi-asserted-by":"crossref","first-page":"17707","DOI":"10.1016\/S0021-9258(19)47429-2","article-title":"Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells","volume":"266","author":"Yoshimori","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.leukres.2018.09.017_bib0115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.molmed.2006.07.007","article-title":"DNA damage-induced cell death by apoptosis","volume":"12","author":"Roos","year":"2006","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.leukres.2018.09.017_bib0120","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett."},{"issue":"33","key":"10.1016\/j.leukres.2018.09.017_bib0125","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1038\/onc.2012.556","article-title":"Various modes of cell death induced by DNA damage","volume":"32","author":"Surova","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.leukres.2018.09.017_bib0130","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1038\/s41598-017-01729-w","article-title":"Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.leukres.2018.09.017_bib0135","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3892\/ijo.2015.3311","article-title":"ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma","volume":"48","author":"Neil","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2018.09.017_bib0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1593\/tlo.13163","article-title":"Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity","volume":"6","author":"Hayman","year":"2013","journal-title":"Transl. Oncol."},{"issue":"13","key":"10.1016\/j.leukres.2018.09.017_bib0145","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood-2011-11-393934","article-title":"Targeting of mTORC1\/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment","volume":"120","author":"Zeng","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2018.09.017_bib0150","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/cas.13431","article-title":"Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia","volume":"109","author":"Kawata","year":"2018","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.leukres.2018.09.017_bib0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nyas.13131","article-title":"Transcription factor EB: from master coordinator of lysosomal pathways to candidate therapeutic target in degenerative storage diseases","volume":"1371","author":"Sardiello","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.leukres.2018.09.017_bib0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.tins.2016.02.002","article-title":"The autophagy-lysosomal pathway in neurodegeneration: a TFEB perspective","volume":"39","author":"Martini-Stoica","year":"2016","journal-title":"Trends Neurosci."},{"issue":"5","key":"10.1016\/j.leukres.2018.09.017_bib0165","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4161\/auto.23965","article-title":"Dual suppressive effect of MTORC1 on autophagy: tame the dragon by shackling both the head and the tail","volume":"9","author":"Zhou","year":"2013","journal-title":"Autophagy"},{"issue":"5","key":"10.1016\/j.leukres.2018.09.017_bib0170","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/emboj.2012.32","article-title":"A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB","volume":"31","author":"Settembre","year":"2012","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.leukres.2018.09.017_bib0175","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016907","article-title":"Lysosomal adaptation: how the lysosome responds to external cues","volume":"6","author":"Settembre","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.leukres.2018.09.017_bib0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev-physiol-012110-142317","article-title":"Lysosomal acidification mechanisms","volume":"74","author":"Mindell","year":"2012","journal-title":"Annu. Rev. Physiol."},{"issue":"2","key":"10.1016\/j.leukres.2018.09.017_bib0185","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.devcel.2004.07.009","article-title":"Role and regulation of starvation-induced autophagy in the Drosophila fat body","volume":"7","author":"Scott","year":"2004","journal-title":"Dev. Cell"},{"issue":"9","key":"10.1016\/j.leukres.2018.09.017_bib0190","first-page":"3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy","volume":"89","author":"Leith","year":"1997","journal-title":"A Southwest Oncol. Group study, Blood"},{"issue":"9","key":"10.1016\/j.leukres.2018.09.017_bib0195","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood.V82.9.2829.2829","article-title":"p53 and N-ras mutations in two new leukemia cell lines established from a patient with multilineage CD7-positive acute leukemia","volume":"82","author":"Abo","year":"1993","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2018.09.017_bib0200","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.bjc.6600036","article-title":"Recurrent growth factor starvation promotes drug resistance in human leukaemic cells","volume":"86","author":"Saeki","year":"2002","journal-title":"Br. J. Cancer"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212618302248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T03:29:30Z","timestamp":1662175770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212618302248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":40,"alternative-id":["S0145212618302248"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2018.09.017","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An mTORC1\/2 kinase inhibitor enhances the cytotoxicity of gemtuzumab ozogamicin by activation of lysosomal function","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2018.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}